---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Model outcomes"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Model outcomes. Topics: Outcomes recommended for budget impact analysis, Outcomes reported by published economic analyses in the indication, and Health-state utility values used in a published cost-effectiveness model. 3 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/model-outcomes"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Model outcomes

<a id="heading-4.2.5"></a>

## 4.2.5 Model Outcomes

<a id="topic-4.2.5-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: model outcomes

No evidence found.

<a id="topic-4.2.5-2"></a>

### Outcomes recommended for budget impact analysis

> “The outcomes of the BIA should be presented in the format of interest to health care decision makers.”
> “In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

> “If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

<a id="topic-4.2.5-3"></a>

### Outcomes reported by published economic analyses in the indication

> “Model outputs included estimates of budget and budget impact in each year over the 3-year period, both on a total plan and a per member per month (PMPM) basis.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

> “The primary outcome was 5-year cost-effectiveness, measured by incremental cost-effectiveness ratio (ICER, calculated as incremental cost divided by incremental effectiveness) and net monetary benefit (NMB, calculated as willingness to pay [WTP] X effectiveness - cost).”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “The total cost per treated patient and total cost per responder, defined as achieving and sustaining CR for ≥12 months was reported at 15 months.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

> “For each population, we estimated time in progression-free state, total costs, total quality-adjusted life-years (QALYs), total equal value life-years gained (evLYGs), and total life-years (LYs) for each treatment over a lifetime time horizon.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

<a id="topic-4.2.5-4"></a>

### Health-state utility values used in a published cost-effectiveness model

| Health state | Utility value | Range | Toll |
| --- | --- | --- | --- |
| Bladder cancer | “0.95” | “0.93–0.97” | “Lifetime” |
| RC/IC (radical cystectomy with ileal conduit) | “0.8” | “0.7–0.9” | “3 months” |
| Post-cystectomy state | “0.9” | “0.8–0.95” | “Lifetime” |
| Metastatic disease | “0.62” | “0.5–0.7” | “Lifetime” |
| Recurrence | “0.8” | “0.75–0.95” | “3 months” |
| Acute minor toxicity (urinary tract infection), disutility | “−0.15” | “0–0.3” | “2 weeks” |
| Acute major toxicity (hospitalization), disutility | “−0.2” | “0–0.3” | “1 month” |

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
